All News
What Lies Beneath: Understanding Nailfold Capillaroscopy
Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation. kin capillaries at the nailfold are evaluated because the fingers are involved in pathological processes such as Raynaud’s phenomenon. Several abstracts and sessions on nailfold capillaroscopy were presented during ACR24.
Read Article
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
ICYMI: Taking AI Out of AutoImmunity: Predicting disease before it develops
the predictive value of a positive ANA test—especially in the absence of other clinical symptoms—remains a challenge. A positive test often leads to further testing, yet it does not necessarily indicate whether a patient truly has an underlying autoimmune disease. The development of AI and machine learning algorithms presents an opportunity to interpret autoantibody tests and predict autoimmune diseases. Here are three studies looking at this issue.
Read Article
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush RheumNow ( View Tweet)
Say Goodbye to Methotrexate in PMR?
Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24
https://t.co/x662FbdNoR https://t.co/uvMPHpmRHZ
Dr. John Cush RheumNow ( View Tweet)
⏩Lecture by Prof Takeuchi on Sjogren Syndrome. Anti-centromere ab is seen in 10% of primary Sjogren syndrome. more likely to have sclerodactyly. https://t.co/mVry2OaNmq @IRACON24Blr https://t.co/SZlWQDpx8B
Links:
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR2024
https://t.co/XJOuKl8lCF https://t.co/XPMlf3sOnU
Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap at #ACR24
Panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Mike Putman and Dr. Jack Cush recap the most interesting abstracts and presentations they saw on day 1 of ACR 2024.
https://t.co/8M0WhOLETg https://t.co/hW5cgRiy6F
Dr. John Cush RheumNow ( View Tweet)
Assessing ASAS Criteria: CLASSIC Study Results
Dr. Adela Castro discusses abstract 0820, presented at #ACR24
https://t.co/rlzL8nAsiI https://t.co/7lbXWE3gdJ
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. Content is chosen by RheumNow & its facult.y
Dr. John Cush RheumNow ( View Tweet)
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at #ACR24
https://t.co/qkDuutgqvv https://t.co/Agqopk6bh2
Dr. John Cush RheumNow ( View Tweet)
SELECT-GCA: Efficacy and Safety of Upadacitinib
Dr. Richard Conway discusses abstract 0770, presented at #ACR24
https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe
Dr. John Cush RheumNow ( View Tweet)
Aging Gracefully in Managing Rheumatic Diseases
Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24.
https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
A new score to quantify GCA inflammation?
The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24… https://t.co/b5H7KOtZPC https://t.co/AvrwHcXI7r
Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA?
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
Gender Differences in SpA
#ACR24 provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented… https://t.co/iEh0s3sIhc https://t.co/SRhz0Uwwwv
Dr. John Cush RheumNow ( View Tweet)
#ACR24 - Day 3 Report
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73
Dr. John Cush RheumNow ( View Tweet)
Health Literacy: the forgotten social determinant of health?
Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/686bWffD2z https://t.co/TFyzgJ3NeL
Dr. John Cush RheumNow ( View Tweet)
Highlights in axSpA
Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24
https://t.co/LvvmzlXWw7 https://t.co/thf9MiMo32
Dr. John Cush RheumNow ( View Tweet)
